These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8950302)

  • 1. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Inoue M; Suzuki T; Kobayashi I; Kodama K; Nagai R
    Life Sci; 1996; 59(23):PL 371-7. PubMed ID: 8950302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
    Takahashi T; Kanda T; Sumino H; Inoue M; Sato K; Sakamaki T; Kobayashi I; Iwamoto A; Nagai R
    Res Exp Med (Berl); 1998 Apr; 197(6):319-28. PubMed ID: 9638794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
    Takahashi T; Kanda T; Inoue M; Sumino H; Kobayashi I; Iwamoto A; Nagai R
    Life Sci; 1998; 63(10):PL137-43. PubMed ID: 9734710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sandostatin inhibits development of medial proliferation of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Murata K
    Life Sci; 1995; 57(8):PL91-5. PubMed ID: 7637546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
    Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
    Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Nagai R
    Res Commun Mol Pathol Pharmacol; 1996 Jan; 91(1):17-32. PubMed ID: 8824928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
    Satoh M; Satoh A
    J Pharm Pharm Sci; 2009 Feb; 11(2):118s-130s. PubMed ID: 19203474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs.
    Ohnishi M; Oka M; Muramatsu M; Sato K; Kira S; Fukuchi Y
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):619-24. PubMed ID: 10218733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
    Dukarm RC; Russell JA; Morin FC; Perry BJ; Steinhorn RH
    Am J Respir Crit Care Med; 1999 Sep; 160(3):858-65. PubMed ID: 10471609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Murata K
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):809-14. PubMed ID: 8850386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension.
    Kang KK; Ahn GJ; Sohn YS; Ahn BO; Kim WB
    J Int Med Res; 2003; 31(6):517-28. PubMed ID: 14708417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semotiadil improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Murata K
    Eur J Pharmacol; 1996 Jan; 295(2-3):229-34. PubMed ID: 8720589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
    Saeki T; Adachi H; Takase Y; Yoshitake S; Souda S; Saito I
    J Pharmacol Exp Ther; 1995 Feb; 272(2):825-31. PubMed ID: 7853200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
    Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of aqueous extract of stem bark of Terminalia arjuna (Roxb.), An ayurvedic drug in experimental pulmonary hypertension.
    Meghwani H; Prabhakar P; Mohammed SA; Seth S; Hote MP; Banerjee SK; Arava S; Ray R; Maulik SK
    J Ethnopharmacol; 2017 Feb; 197():184-194. PubMed ID: 27401289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
    Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
    Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
    Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.